All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-11-18T16:24:27.000Z

When will we be seeing changes in the frontline treatment of DLBCL?

Nov 18, 2020
Share:

Bookmark this article

During the European School of Haematology (ESH)'s 2nd How to Diagnose & Treat Lymphoma conference, the Lymphoma Hub spoke to Andrew Davies, University of Southampton, Southampton, UK. We asked, When will we be seeing changes in the frontline treatment of diffuse large B-cell lymphoma (DLBCL)?

When will we be seeing changes in the frontline treatment of DLBCL?

Andrew Davies starts by describing the changes in treatment selection that has already started to occur for patients with standard risk disease. He then discusses the situation for patients with high-risk DLBCL, which is yet to undergo such a shift. The different approaches that have been tested are listed, but it is acknowledged that R-CHOP protocols remain the standard of care for this group. The impact of molecular profiling and patient stratification are examined.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox